This study, which may have direct implications for treatment, explains why some actinic keratoses recur and progress after superficial destructive treatments — like cryotherapy.
Optimal management of psoriasis symptoms falls short for about three in 10 patients with moderate plaque psoriasis and one in five with severe psoriasis, a study shows.
The incoming editor of the Journal of the American Academy of Dermatology wants to spark discussion. He views publishing as a way to provide, interpret, and show application of new information
In this article, Dr. Murad Alam, M.D., president elect of the American Society for Dermatologic Surgery, addresses how changes in federal and state regulations that govern compounding medications could impact physicians and patients.
Physicians should be aware of the warning signs that a biologic agent could be to blame when patients experience subacute or rapidly progressive neurologic changes, researchers say.
Acute or irregular flushing may signal a more serious health condition, say researchers who list 14 questions physicians should ask patients complaining about unusual flushing.
A phase two study of adults with moderate-to-severe atopic dermatitis shows that once-daily oral Janus kinase (JAK) 1 and 2 inhibitor baricitinib relieved itch and improved sleep, a study shows.
Moderate-to-severe psoriasis and psoriatic arthritis patients are more likely than people without these conditions to have cardiovascular and mental comorbidities, as well as higher healthcare utilization and medical costs, primarily from pharmacy-related expenses, according to a recent retrospective study of U.S. Department of Defense patients.
The risk of death for adults with psoriasis that impacts more than 10 percent of body surface area is about 1.8 times greater than adults without psoriasis, according to a new study.
Knowledge of outcomes data, adverse events may help physicians formulate effective treatment strategies, Dr. April Armstrong says.